One strategy to combine the benefits of a tumor-restricted CD47 blockade with a pro-phagocytic stimulus in a single molecule is to fuse SIRPα with a tumor-associated antigen (TAA)-specific IgG1 antibody. The gene discussed is SIRPA; the disease is neoplasm.